FGF23 in Acute and Chronic Illness.
FGF23 is a bone-derived phosphaturic hormone that may become a useful biomarker for the identification of high-risk patients in chronic but also acute disease. It rises early in chronic kidney disease and is strongly and independently associated with excess morbidity and mortality. Emerging data suggest that FGF23 is also elevated in different scenarios of acute illness. In this review, we give an overview on the role of this interesting disease marker and potential and proven interventional strategies and discuss a blueprint for future research.
Division of Vascular and Interventional Radiology, Department of Radiology, Medical University of Graz, 8036 Graz, Austria.
Christian
C
Schnedl
Department of Endocrinology and Metabolism, Medical University of Graz, 8036 Graz, Austria.
Astrid
A
Fahrleitner-Pammer
Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Wien, Austria.
Peter
P
Pietschmann
Department of Endocrinology and Metabolism, Medical University of Graz, 8036 Graz, Austria.
Karin
K
Amrein
D000818:Animals; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000097:blood*; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood* / Q000378:metabolism; D006801:Humans; D051436:Renal Insufficiency, Chronic / Q000097:blood*; D018805:Sepsis / Q000097:blood*
D015415:Biomarkers; C000717427:FGF23 protein, human; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23